Welcome to our dedicated page for Pasithea Therapeutics SEC filings (Ticker: KTTAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pasithea Therapeutics Corp. (KTTA, KTTAW) SEC filings page on Stock Titan brings together the company’s official disclosures as a clinical-stage biotechnology issuer listed on The Nasdaq Capital Market. Through documents such as Forms 10-K, 10-Q, 8-K, S-1 and proxy statements, Pasithea reports on its development of PAS-004, a macrocyclic oral MEK inhibitor for NF1-associated plexiform neurofibromas, advanced cancers, ALS and other MAPK pathway-related diseases, as well as on its capital structure and governance decisions.
Current reports on Form 8-K provide timely information on material events, including notices from Nasdaq regarding minimum bid price compliance, changes to at-the-market offering capacity, annual meeting dates and outcomes, and shareholder approvals of items such as stock incentive plan amendments and potential reverse stock splits. These filings help investors understand listing status, financing flexibility and board-authorized corporate actions that may affect KTTA common stock and KTTAW warrants.
Proxy materials and registration statements, such as definitive proxy statements (DEF 14A) and Form S-1 filings, outline proposals submitted to stockholders, including director elections, auditor ratification, equity plan changes and reverse split authorizations, as well as the terms and intended use of proceeds for public offerings. They also describe how Pasithea plans to fund ongoing research, clinical trials and technology development.
On Stock Titan, each new Pasithea filing is captured from EDGAR and paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see what changed in a filing, how it relates to PAS-004 clinical programs, equity offerings, incentive plans or Nasdaq compliance, and then drill down into the full text when deeper review is needed. This structure supports efficient tracking of KTTA and KTTAW regulatory disclosures, from routine reports to significant corporate events.
Pasithea Therapeutics (Nasdaq:KTTA) filed an 8-K reporting receipt of a Nasdaq bid-price deficiency notice on 23-Jun-2025. The company’s shares traded below the $1.00 minimum for 30 consecutive business days, violating Listing Rule 5550(a)(2). Pasithea has 180 days—until 22-Dec-2025—to regain compliance by posting a closing bid of at least $1.00 for 10 straight sessions. A second 180-day extension is possible if other listing standards are met and the firm commits to a remedy such as a reverse split. There is no immediate delisting; business operations and SEC reporting remain unaffected. Management is monitoring share price and evaluating options to restore compliance.